{"id":"W2588076823","doi":"10.1093/annonc/mdw435.22","title":"genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Eisai; GlaxoSmithKline Australia; Exelixis; Roche; Bayer; Novartis; British Microcirculation Society; Pfizer","keywords":"Medicine; Clinical endpoint; Renal cell carcinoma; Adverse effect; Urology; Placebo; Internal medicine; Sunitinib; Nephrectomy; Surgery; Randomized controlled trial; Kidney; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008471237,0.001049394,0.002086118,0.0002951549,0.000429242,0.001096745,0.0007731288,0.001005096,0.006083378],"category_scores_gemma":[0.000729924,0.0004531296,0.00172376,0.0003498112,0.0009305399,0.0006427244,0.0002803611,0.002979908,0.0008457131],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007330463,"about_ca_system_score_gemma":0.001387604,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002428241,"about_ca_topic_score_gemma":0.01290073,"domain_scores_codex":[0.9997796,0.00009561759,0.000009147944,0.0000476825,0.00001637237,0.00005153359],"domain_scores_gemma":[0.9995525,0.00007752073,0.00008841239,0.00003242757,0.00002269404,0.0002264858],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9458325,0.009091233,0.001466241,0.0007425434,0.001280027,0.00006586081,0.0001010375,0.0007080279,0.007212692,0.0001809421,0.002294831,0.03102406],"study_design_scores_gemma":[0.8389652,0.1490471,0.007697213,0.00005084432,0.0009810642,0.0001089805,0.00006695941,0.000595385,0.0009754261,0.0002136068,0.001277021,0.00002127423],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907691,0.003915694,0.0002177654,0.000609105,0.0004229662,0.000621666,0.0009417408,0.0001097121,0.002392338],"genre_scores_gemma":[0.9886441,0.002260394,0.0006001443,0.0007934645,0.0002368657,0.000559141,0.00131717,0.00002789146,0.005560823],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006083378,"threshold_uncertainty_score":0.02035087,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04961390079722365,"score_gpt":0.3496073487410085,"score_spread":0.2999934479437848,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}